CELLINK’s financial targets for the period 2019-2022 are as follows:
CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions. CELLINK’s Board targets a profitable growth, therefore CELLINK shall show a positive EBITDA margin during the period 2019-2022. CELLINK’s board considers that CELLINK should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times.
Goals in summary:
- Organic sales growth of >35% per year
- Showing a positive EBITDA margin
- Net debt in relation to EBITDA <3.0
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 13, 2019 at. 08:30 CET.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at [email protected].
at: [email protected].